UA138184U - METHOD FOR PREDICTING THE DEVELOPMENT OF OSTEOARTHRITIS - Google Patents

Abstract

The method of predicting the development of osteoarthritis includes clinical examination and radiography. Additionally, the polymorphism of methylenetetrahydrofolate reductase (MTHFR C677T), nitric oxide synthase (eNOS T786C), thrombomodulin, folic acid, cartilaginous oligomeric matrix protein (COM) is determined in the patient's serum. With a homozygous carrier of 677-TT, 786-CC and levels of thrombomodulin> 5 ng / ml, folic acid <6 ng / ml, COMP> 595 ng / ml predict the development of osteoarthritis.

Description

The proposed useful model for predicting the development of osteoarthritis belongs to medicine, in particular to orthopedics and rheumatology. It is prescribed and can be used in diagnosing the development of osteoarthritis in the early stages.

Methods of predicting the development of osteoarthritis are known. These include x-rays, studies of biopsies of the synovial membrane, synovial fluid, and cartilage biopsies (A.N.

Okorokov Diagnosis of diseases of internal organs. - M., 2001. - Vol. 2. - P. 186-196). The disadvantage of these methods is the lack of the possibility of predicting the dynamics of the process in the early subclinical stages, preventing its development and possible complications due to the internal characteristics of the body.

The basis of a useful model is the task of developing a method that would allow predicting the development of osteoarthritis in the early stages.

The set task is solved by the fact that, in addition to clinical examination and radiography, polymorphism of methylenetetrahydrofolate reductase genes (MTNEV) is determined in the patient's blood serum

Сб77Т), nitric oxide synthase (eMOB5 17860), the content of thrombomodulin, folic acid, cartilage oligomeric matrix protein (COMP). With homozygous carrier 677-177, 786-SS, levels of thrombomodulin "5 ng/ml, folic acid "6 ng/ml, SOMR "595 ng/ml predict the development of osteoarthritis.

Application of the method. During hospitalization, the patient is examined, x-rays are taken, the polymorphism of MTNEV C677T, eMmo5 T786C genes is determined, the content of thrombomodulin, folic acid, and SOMR is determined by the immunoenzymatic method. With homozygous carriers of 677-TT, 786-SS, levels of thrombomodulin "5 ng/ml, folic acid "b ng/ml, SOMR "595 ng/ml predict the development of osteoarthritis.

A specific example of using the method.

Patient R., 62 years old, was hospitalized for pain in the left knee joint. Examined, X-ray taken. No signs of osteoarthritis were found. The polymorphism of MTNEV C677T and emo5 17860 genes was determined in blood serum. The content of thrombomodulin, folic acid, and SOMP was determined by immunoenzymatic method. A homozygous carrier of 677-TT and 786-SS was established, the levels of thrombomodulin - 13 ng/ml, folic acid - 3.2 ng/ml, COMP - 685 ng/ml. The development of osteoarthritis was diagnosed. After 11 months, X-rays revealed

From the phenomenon of osteoarthritis.

Thus, the proposed method is informative and allows diagnosing the development of osteoarthritis at an early stage.

Claims (1)

USEFUL MODEL FORMULA The method of predicting the development of osteoarthritis, which includes a clinical examination, radiography, which is distinguished by the fact that the polymorphism of the methylenetetrahydrofolate reductase (MTNEV С677Т), nitric oxide synthase (ЕМО5 1786С), content of thrombomodulin, folic acid, cartilage oligomeric matrix protein ( COMP) and with homozygous carrier 677-TT, 786-SS and levels of thrombomodulin "5 ng/ml, folic acid "6 ng/ml, COMP "595 ng/ml predict the development of osteoarthritis.